Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 4
2020 3
2021 1
2022 2
2023 11
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug Conjugates.
Thomas JD, Yurkovetskiy AV, Yin M, Bodyak ND, Tang S, Protopopova M, Kelleher E, Jones B, Yang L, Custar D, Catcott KC, Demady DR, Collins SD, Xu L, Bu C, Qin L, Ter-Ovanesyan E, Damelin M, Toader D, Lowinger TB. Thomas JD, et al. Mol Cancer Ther. 2024 Apr 2;23(4):541-551. doi: 10.1158/1535-7163.MCT-23-0622. Mol Cancer Ther. 2024. PMID: 38354416
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.
Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, Bilen MA, Lolkema MP, Adra N, Rottey S, Greil R, Matsubara N, Tan DSW, Wong A, Uemura H, Lemech C, Meran J, Yu Y, Minocha M, McComb M, Penny HL, Gupta V, Hu X, Jurida G, Kouros-Mehr H, Janát-Amsbury MM, Eggert T, Tran B. Dorff T, et al. Clin Cancer Res. 2024 Apr 15;30(8):1488-1500. doi: 10.1158/1078-0432.CCR-23-2978. Clin Cancer Res. 2024. PMID: 38300720 Clinical Trial.
Predicting the Abscopal Phenomenon-Reply.
Nelson BE, Subbiah V. Nelson BE, et al. Mol Cancer Ther. 2024 Feb 1;23(2):250. doi: 10.1158/1535-7163.MCT-23-0581. Mol Cancer Ther. 2024. PMID: 38298151 No abstract available.
The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy.
Koh DI, Lee M, Park YS, Shin JS, Kim J, Ryu YS, Lee JH, Bae S, Lee MS, Hong JK, Jeong HR, Choi M, Hong SW, Kim DK, Lee HK, Kim B, Yoon YS, Jin DH. Koh DI, et al. Cancer Immunol Res. 2024 Apr 2;12(4):491-507. doi: 10.1158/2326-6066.CIR-23-0817. Cancer Immunol Res. 2024. PMID: 38289363
34 results